Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpFN + ALFQ Vaccine for COVID-19 Prevention
NCT04784767Phase 1Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Apr 2021
- Primary completion
- Mar 2023
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of spike ferritin nanoparticle in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Number of participants with local and systemic reactions, Incidents of treatment-adverse events and 1 more. Started Apr 2021; status: completed.
02
Drugs
spike ferritin nanoparticle
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04784767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784767.